Takeda Pharmaceutical (TAK) Other Non Operating Income (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Other Non Operating Income of $246.2 million for Q2 2026, up 6.64% year-over-year from $230.8 million in Q2 2025, and little changed quarter-over-quarter from $245.5 million in Q1 2026.
Takeda Pharmaceutical (TAK) Other Non Operating Income (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Other Non Operating Income history runs 10 years deep, the most recent figure standing at $246.2 million for Q2 2026.
- In Q2 2026, Other Non Operating Income rose 6.64% year-over-year to $246.2 million; the TTM figure through Jun 2026 stood at $986.9 million (down 12.11% YoY), while the FY2026 annual figure was $972.5 million, down 9.4% from the prior year.
- Other Non Operating Income for Q2 2026 stood at $246.2 million, roughly flat from $245.5 million in the prior quarter.
- The five-year high for Other Non Operating Income was $431.3 million in Q3 2024, with the low at -$250.2 million in Q1 2023.
- The 5-year median for Other Non Operating Income is $245.8 million (2026), against an average of $194.4 million.
- The sharpest annual moves came in 2022 and 2023: Other Non Operating Income slumped 182.71% in 2022, then jumped 672.85% in 2023.
- Takeda Pharmaceutical's Other Non Operating Income stood at $269.5 million in 2022, then increased by 12.42% to $302.9 million in 2023, then slipped by 16.22% to $253.8 million in 2024, then decreased by 8.45% to $232.3 million in 2025, then increased by 5.95% to $246.2 million in 2026.
- Business Quant data shows TAK's Other Non Operating Income at $246.2 million in Q2 2026, $245.5 million in Q1 2026, and $232.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Alkermes | 8.11 Bn | 7.46 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 246.17 Mn |
| Mar 31, 2026 | 245.48 Mn |
| Dec 31, 2025 | 232.34 Mn |
| Sep 30, 2025 | 262.93 Mn |
| Jun 30, 2025 | 230.83 Mn |
| Mar 31, 2025 | 206.99 Mn |
| Dec 31, 2024 | 253.80 Mn |
| Sep 30, 2024 | 431.33 Mn |
| Jun 30, 2024 | 186.38 Mn |
| Mar 31, 2024 | 277.97 Mn |
| Dec 31, 2023 | 302.95 Mn |
| Sep 30, 2023 | 336.96 Mn |
| Jun 30, 2023 | 241.67 Mn |
| Mar 31, 2023 | -250.23 Mn |
| Dec 31, 2022 | 269.47 Mn |
| Sep 30, 2022 | 282.53 Mn |
| Jun 30, 2022 | -42.19 Mn |
| Mar 31, 2022 | -216.84 Mn |
| Dec 31, 2021 | 374.42 Mn |
| Sep 30, 2021 | 298.06 Mn |